CN-122005612-A - Application of lanolin in preparation of alopecia-resistant product

Abstract

The invention discloses application of lanolin in preparing an anti-alopecia product, wherein alopecia comprises androgenetic alopecia, and the product comprises lanolin and auxiliary materials. The invention excavates candidates from the existing skin care product raw material library, verifies the treatment effect of lanolin on androgenetic alopecia through in vivo and in vitro experiments, provides a brand new application of lanolin, verifies good safety through long-term human external use, can realize local accurate effect through a transdermal delivery system, and avoids systematic risks of oral medicines. The invention proves that the lanolin has the effect of treating androgenetic alopecia, and compared with the existing single-mechanism therapeutic drug, the lanolin has less side effect in the aspect of treating androgenetic alopecia and has good long-term use tolerance.

Inventors

• WANG YAO
• ZHOU YUQING
• GUAN JINGSONG
• WANG CHUANG

Assignees

• 广西中医药大学

Dates

Publication Date

20260512

Application Date

20260409

Claims (10)

1. 1. Application of lanolin in preparing alopecia resisting product is provided.
2. 2. The use according to claim 1, wherein the hair loss comprises androgenic alopecia.
3. 3. The use according to claim 1, wherein the product comprises lanolin and an adjuvant.
4. 4. Use according to claim 1, wherein the product comprises a pharmaceutical and/or cosmetic product.
5. 5. The use according to claim 4, wherein the lanolin content of the cosmetic product is 1% -35%.
6. 6. The use according to claim 4, wherein lanolin is administered in the medicament at a concentration of 1-100 μg/mL.
7. 7. An anti-hair loss product, characterized in that the active ingredient of the product comprises lanolin.
8. 8. The product of claim 7, wherein the hair loss comprises androgenetic hair loss.
9. 9. The product of claim 7, further comprising an adjunct.
10. 10. The product according to claim 7, characterized in that it comprises pharmaceutical and/or cosmetic products; preferably, the lanolin content in the cosmetic is 1% -35%; preferably, lanolin is administered at a concentration of 1-100 μg/mL in the pharmaceutical product.

Description

Application of lanolin in preparation of alopecia-resistant product Technical Field The invention belongs to the technical field of biological medicines, and particularly relates to application of lanolin in preparation of an anti-hair loss product. Background Androgenetic alopecia (Androgenetic alopecia, AGA) is the most common non-scarring alopecia worldwide, affects about 10 hundred million patients, has prevalence of 21.3% for men and 6% for women in adults, and presents a younger trend, often causing psychological problems such as anxiety, social disorders, and the like. The pathogenesis of the hair follicle is related to multiple functions of genetic susceptibility, androgen mediation and hair follicle microenvironment abnormality, and the hair follicle is driven by the genetic susceptibility and androgen signal abnormality together, so that the dihydrotestosterone excessively activates the hair follicle androgen receptor, thereby leading to hair follicle micromation, shortened growing period and finally hair sparsity and abscission. The existing treatments are mainly minoxidil (external use) and finasteride (oral administration), the former is used for promoting hair growth by improving hair follicle microcirculation, and the latter is used for inhibiting 5 alpha-reductase and reducing dihydrotestosterone production, and is a long-term mainstream scheme. But has the problems of limited curative effect, obvious side effect, limited applicable crowd (finasteride forbidden to females), single target point and the like. The existing therapy is difficult to meet clinical demands, and development of innovative drugs with multiple targets, high efficiency and safety has become an urgent task. In recent years, external androgen receptor antagonists have become breakthrough directions, clascoterone, pirutamine and the like enter phase III clinic, and the overall adverse reaction is reduced while the hair density is improved. In addition, topical finasteride, JAK inhibitors, hair follicle microenvironment regulation and stem cell therapies are also actively under development, providing new possibilities for combination therapies. The research and development of the prior AGA medicament focuses on androgens (such as testosterone and DHT) as targets, and plays a role by inhibiting the synthesis of the androgens (such as finasteride for inhibiting 5 a-reductase), but the strategy has obvious limitations that on one hand, long-term administration is easy to induce activation of androgen synthesis compensatory passages to cause drug resistance, on the other hand, the androgens are systemic hormones, and the dry prognosis possibly affects the functions of other organs such as gonads and the like, so that the safety is doubtful. Traditional medicines also have the problems of sexual function influence, teratogenesis risk, re-release after stopping medicines and the like. Lanolin and its derivatives have stable chemical properties, strong emulsifying power and similar performance to human sebum, and are widely used in the fields of cosmetics, medicine, leather and other fine chemical industry. Lanolin and its derivatives can be used as emulsifier, humectant, lubricant, spreading agent, penetrant, solubilizer, and care agent in cosmetic field, and as medicinal adjuvants, ointment base, and emulsifier in pharmaceutical field. Lanolin has not been reported for the treatment of androgenic alopecia. Disclosure of Invention The present invention aims to solve at least one of the technical problems in the prior art described above. Therefore, the invention provides application of lanolin in preparing anti-alopecia products, candidates are excavated from the existing skin care product raw material library, the treatment effect of lanolin on androgenetic alopecia is verified through in-vivo and in-vitro experiments, a brand new application of lanolin is provided, the safety is good through long-term human external verification, and the local accurate effect can be realized through a transdermal delivery system, so that the systemic risk of oral medicines is avoided. The invention proves that the lanolin has the function of treating AGA, and compared with the existing single-mechanism therapeutic drug, the lanolin has less side effect in the aspect of treating AGA and has good long-term use tolerance. The invention also provides an anti-hair loss product. According to a first aspect of the present invention there is provided the use of lanolin in the manufacture of an anti-hair loss product. The invention breaks through the traditional target selection, turns to androgen receptor (Androgen receptor, AR), which is used as a core effector molecule of androgen signal transmission, has larger molecular weight and long intracellular metabolism period, is not easy to generate drug resistance through mutation, and can avoid systemic adverse reaction by local application of scalp. The present invention focuses on the direction of AR de